From: Cortical microstructure in primary progressive aphasia: a multicenter study
 | PPA |  |  |  |  | HC |
---|---|---|---|---|---|---|
 | nfvPPA n=52 (43%) | svPPA n=31 (26%) | lvPPA n=32 (27%) | PPA-GRN n=5 (4%) | All PPA n=120 (100%) | HC n=89 |
Cohort, no. (CATFI/UCSF) | 18/34 | 15/16 | 11/21 | 3/2 | 47/73†| 54/35†|
Demographics, genetic, and clinical features | Â | Â | Â | Â | Â | Â |
 Age at MRI, years | 69.0 (7.3) | 67.1 (7.5) | 66.3 (7.9) | 61.7 (3.3) | 67.5 (7.5) | 66.0 (6.9) |
 Biological sex (men/women) | 20/32 | 16/15 | 16/16 | 0/5 | 52/68 | 31/58 |
 APOEɛ4, no. (positive/negative) | 9/39 | 4/21 | 9/18 | 0/4 | 22/82 | 7/28 |
 Education, years | 14.2 (5.2) | 14.6 (4.0) | 13.1 (7.2) | 12.4 (5.7) | 13.9 (5.5) | 14.7 (4.4) |
 Handedness (right/left) | 45/7 | 28/3 | 29/3 | 4/1 | 106/14 | 85/4 |
 Disease duration at MRI, years | 4.2 (2.3) | 4.5 (3.2) | 4.1 (1.8) | 2.5 (1.6) | 4.2 (2.4) | - |
Measures of cognition and disease severity | Â | Â | Â | Â | Â | Â |
 MMSE, /30 | 25.0 (4.6)‡ | 23.9 (4.6) | 20.7 (6.2)‡ | 27.0 (2.6)‡ | 23.7 (5.3)†| 29.1 (0.9)†|
 CDR® plus NACC FTLD-SB, /24a | 3.9 (2.6)§ | 6.3 (3.2)§ | 5.1 (2.8) | 3.8 (4.6) | 4.9 (3.0)†| 0.0 (0)†|
 Global CDR® plus NACC FTLD = 0.5, no. (%) | 20 (38) | 6 (19) | 9 (28) | 1 (20) | 36 (30)†| 0 (0)†|
Biomarkers and autopsy findings | Â | Â | Â | Â | Â | Â |
 Amyloid PET, no. (positive/negative) | 0/21 | 1/6 | 13/0 | 0/0 | 14/27 | 1/1 |
 AD biomarkers in CSF, no. (Positive/Negative)b | 3/12 | 2/12 | 9/0 | 0/2 | 14/26 | 5/27 |
 Pathological diagnosis, no. (FTLD/AD)c | 16/0 | 3/0 | 0/8 | 2/0 | 21/8 | 0/0 |